Literature DB >> 35088121

Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.

Lorenzo Pelizza1, Emanuela Leuci2, Davide Maestri2, Emanuela Quattrone2, Silvia Azzali3, Giuseppina Paulillo2, Pietro Pellegrini2.   

Abstract

Negative symptoms (NS) severely interfere with real-world performance, already at the onset of schizophrenia and in "clinical high risk" mental states. However, most of the empirical studies specifically examining treatment effectiveness on NS included patients with stable, prolonged schizophrenia. Moreover, research on psychosocial interventions for NS in early schizophrenia is still relatively scarce. Thus, the aims of this study were (1) to longitudinally monitor the NS stability in young individuals with First Episode Schizophrenia (FES) across a 2-year follow-up period, and (2) to investigate any significant association of NS with functioning, other aspects of FES psychopathology and the specific treatment component effects on NS of an "Early Intervention in Psychosis" (EIP) program during the 2 years of follow-up. At entry, 159 FES participants (aged 12-35 years) completed the Positive And Negative Syndrome Scale (PANSS) and the Global Assessment of Functioning (GAF). Spearman's correlations and multiple linear regression analyses were performed. NS had relevant enduring associations with PANSS disorganization scores and GAF functioning decline. Across the follow-up, FES individuals showed a significant improvement in NS levels. This was specifically associated with the number of individual psychotherapy and intensive case management sessions provided during the 2 years of our EIP program, as well as with the antipsychotic dosage at entry. NS are clinically relevant in FES, already at the enrollment in specialized EIP services. However, their clinical severity seems to decrease over time, together with the delivery of specific, patient-tailored EIP interventions.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Early intervention; Early schizophrenia; First episode schizophrenia; Follow-up; Negative symptoms; Treatment response

Mesh:

Substances:

Year:  2022        PMID: 35088121     DOI: 10.1007/s00406-021-01374-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  49 in total

1.  Negative symptom configuration in first episode Schizophrenia: findings from the "Parma Early Psychosis" program.

Authors:  Lorenzo Pelizza; Giulia Landi; Clara Pellegrini; Emanuela Quattrone; Silvia Azzali; Pietro Pellegrini; Emanuela Leuci
Journal:  Nord J Psychiatry       Date:  2019-11-25       Impact factor: 2.202

2.  Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project.

Authors:  Michele Poletti; Lorenzo Pelizza; Silvia Azzali; Federica Paterlini; Sara Garlassi; Ilaria Scazza; Luigi Rocco Chiri; Eva Gebhardt; Simona Pupo; Raballo Andrea
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-12-01       Impact factor: 4.785

3.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

4.  Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application.

Authors:  Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

Review 5.  Negative symptoms of schizophrenia: new developments and unanswered research questions.

Authors:  Silvana Galderisi; Armida Mucci; Robert W Buchanan; Celso Arango
Journal:  Lancet Psychiatry       Date:  2018-03-27       Impact factor: 27.083

6.  Negative symptom configuration within and outside schizophrenia spectrum disorders: results from the "Parma Early Psychosis" program.

Authors:  Lorenzo Pelizza; Davide Maestri; Emanuela Leuci; Emanuela Quattrone; Silvia Azzali; Giuseppina Paulillo; Pietro Pellegrini
Journal:  Psychiatry Res       Date:  2020-10-26       Impact factor: 3.222

Review 7.  Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.

Authors:  Nina R Schooler; Robert W Buchanan; Thomas Laughren; Stefan Leucht; Henry A Nasrallah; Steven G Potkin; Danielle Abi-Saab; Carmen Galani Berardo; Dragana Bugarski-Kirola; Thomas Blaettler; Chris J Edgar; Anna-Lena Nordstroem; Cedric O'Gorman; George Garibaldi
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

Review 8.  Pathophysiology of negative symptom dimensions of schizophrenia - Current developments and implications for treatment.

Authors:  Indrit Bègue; Stefan Kaiser; Matthias Kirschner
Journal:  Neurosci Biobehav Rev       Date:  2020-06-10       Impact factor: 8.989

9.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

10.  Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm.

Authors:  Giancarlo Cerveri; Camilla Gesi; Claudio Mencacci
Journal:  Neuropsychiatr Dis Treat       Date:  2019-06-05       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.